The nonsurgical management of early stage (T1/2 N0 M0) laryngeal cancer: A population analysis

被引:2
|
作者
Lee, Kevin C. [1 ]
Chuang, Sung-Kiang [2 ,3 ]
机构
[1] New York Presbyterian Columbia Univ, Irving Med Ctr, Div Oral & Maxillofacial Surg, New York, NY USA
[2] Univ Penn, Dept Oral & Maxillofacial Surg, Philadelphia, PA 19104 USA
[3] Brockton Oral & Maxillofacial Surg Inc, Dept Oral & Maxillofacial Surg, Good Samaritan Med Ctr, Brockton, MA USA
关键词
SQUAMOUS-CELL CARCINOMA; EARLY GLOTTIC CANCER; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; PROGNOSTIC-FACTORS; LOCAL-CONTROL; RADIOTHERAPY; PRESERVATION; CHEMOTHERAPY; SURGERY;
D O I
10.1016/j.oooo.2020.01.006
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background. The purpose of this study was to evaluate the patterns of care and survival in the nonsurgical management of early-stage (T1/2 N0 M0) laryngeal cancer. Study Design. This was a retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) database during the period 2004 to 2015. Patients diagnosed with T1/2 N0 M0 laryngeal SCC definitively treated without surgery were included. Study predictors were age, gender, race, marital status, histologic grade, stage, and management strategy defined as radiotherapy (RT), chemotherapy, chemoradiotherapy (CRT), or no treatment. Study outcomes were overall survival (OS) and disease-specific survival (DSS). Results. In total, 3221 patients comprised the final sample. Over half of the lesions were stage I (63.8%); 74.0%, 24.8%, and 1.2% were located in the glottis, supraglottis, and subglottis, respectively. RT (77.6%) was the preferred nonsurgical treatment modality, followed by CRT (12.7%). A greater proportion of patients with stage II disease (25.1%) received CRT compared with those with stage I (5.6%). Similarly, patients receiving CRT were significantly younger and more likely to present with higher-grade lesions located in the supraglottis and subglottis. In the multivariate model, the risks of both disease-specific and overall death were increased by age, male gender, supraglottic and subglottic location, stage II disease, CRT, and no treatment. Conclusions. Definitive RT was the preferred treatment modality regardless of tumor characteristics. CRT was more often selectively reserved for younger patients with higher grade, stage II tumors located in the supraglottis and subglottis. This approach may be driven by the poorer rates of survival associated with these particular characteristics. CRT did not appear to improve survival in comparison with RT after controlling for subsite and disease severity; however, future clinical studies are required to validate this finding.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 50 条
  • [31] Prognostic value of histology grade and ki67 index in breast cancer (T1-2 N0 M0)
    Kudaybergenova, A.
    Rusaln, P.
    Komyahov, A.
    VIRCHOWS ARCHIV, 2015, 467 : S56 - S56
  • [32] BILATERAL RADICAL MASTECTOMY FOR CARCINOMA OF BREAST OF STAGES T0 AND T1(N0, M0) AND MAMMOPLASTY OF BOTH BREASTS, AREOLA AND NIPPLES IN A SINGLE OPERATION
    HUTER, J
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1976, 36 (01) : 10 - 19
  • [33] The treatment of early laryngeal cancers (T1-T2 N0): Surgery or irradiation?
    Jones, AS
    Fish, B
    Fenton, JE
    Husband, DJ
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2004, 26 (02): : 127 - 135
  • [34] THE ROLE OF ADJUVANT THERAPY AFTER RESECTION OF T1 N1 M0 AND T2 N1 M0 NON-SMALL CELL LUNG-CANCER
    FERGUSON, MK
    LITTLE, AG
    GOLOMB, HM
    HOFFMAN, PC
    DEMEESTER, TR
    BEVERIDGE, R
    SKINNER, DB
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1986, 91 (03): : 344 - 349
  • [35] Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: A single-institution study
    Kodama, K
    Doi, O
    Higashiyama, M
    Yokouchi, H
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (03): : 347 - 353
  • [36] Radical Cystectomy vs. Chemoradiation for the Treatment of T24a N0 M0 Bladder Cancer
    Klautke, Gunther
    STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 (11) : 823 - 824
  • [37] Management of Clinical Stage T1N0M0 Esophageal Cancer
    Yang, A. J.
    Choi, S.
    Byun, H. K.
    Kim, H. J.
    Choi, J.
    Lee, C. G., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E45 - E45
  • [38] Fluorescence in situ hybridization (FISH) analysis of c-myc amplification in Stage T3 N0 M0 prostate cancer in Japanese patients
    Sato, H
    Hachiya, T
    Ishida, H
    Okada, K
    Takimoto, Y
    JOURNAL OF UROLOGY, 2003, 169 (04): : 161 - 162
  • [39] RADICAL CYSTECTOMY FOR HISTORICAL AND PATHOLOGIC-T1, N0, M0 (STAGE-A) TRANSITIONAL CELL-CANCER - NEED FOR ADJUVANT SYSTEMIC CHEMOTHERAPY
    SIREF, LE
    ZINCKE, H
    UROLOGY, 1988, 31 (04) : 309 - 311
  • [40] T&G: an elementary integrated prognostic system for renal carcinoma N0 M0
    Legramanti, Stefano
    Antonelli, Alessandro
    Arrighi, Nicola
    Corti, Serena
    Zanotelli, Tiziano
    Cozzoli, Alberto
    Cunico, Sergio Cosciani
    Simeone, Claudio
    UROLOGIA JOURNAL, 2012, 79 : 76 - 79